Dvořák, M, Dvořáková M, Karafiát V, Štursa J, Werner L. Derivatives of phospholipids and their use as pharmaceuticals

Grekov I, Pombinho A, Šíma M, Kobets T, Bartůněk P, Lipoldová M. Pharmaceutical composition consisting of diphenyleneiodonium for treating diseases caused by the parasites belonging to the family trypanosomatidae

Kotora M, Prchalová E, Adamski J, Moller G, Stěpánek O, Bartůněk P, Sedlák D, Hajduch M, Dzubak P. 15β-substituted estrone derivatives as selective inhibitors of 17β-hydroxysteoid dehydrogenases

Stoniš J, Mikeš I, Doležalová A, Králová J, Jakubek M, Martásek P, Král V. Orodispersible tablet with bioavailable curcumin and its use.

Havlík M, Bříza T, Kaplánek R, Králová J, Martásek P, Král V. The coumarin derivative of the Tröger base with cyanine substitution and its use

Staňková P, Štěpán J, Demele J, Slováček Z, Králová J, Martásek P, Král V. A supramolecular complex of an oxycellulose matrix with a taxol derivative with sequential release of the taxol derivative and its use.

Staňková P, Štěpán J, Demele J, Slováček Z, Králová J, Martásek P, Král V.  A supramolecular complex of an oxycellulose matrix with an anthracycline cytostatic with sequential release of an anthracycline cytostatic and its use.

Havlík M, Bříza T, Kejík Z, Dolenský B, Kaplánek R, Rak J, Králová J, Šedo A,Martásek P, Král V. A symmetric derivative of Tröger's base with tetramethine substitution and its use.

Havlík M, Bříza T, Kejík Z, Dolenský B, Kaplánek R, Rak J, Králová J, Šedo A,Martásek P, Král V.  An asymmetric derivative of Tröger's base with tetramethinium substitution and its use.

Grekov I, Pombinho A, Šíma M, Kobets T, Bartůněk P, Lipoldová M. Pharmaceutical composition comprising diphenyleneiodonium for treating diseases caused by the parasites belonging to the family Trypanosomatidae.

Havlík M, Bříza T, Kejík Z, Dolenský B, Kaplánek R, Rak J, Králová J, Šedo A, Martásek P,  Král V. An asymmetric derivative of Tröger's base with dimethinium substitution and its use.

Kral V, Havlik M, Kaplanek R, Dolensky B, Ruml T, Rimpelova S, Martasek P, Briza T, Kejik Z, Rak J, Kralova J. Pentamethinium salts with an expanded quinoxaline unit and its use in anticancer therapy.

Bartůněk P, Kořínek V, Pombinho A, Tůmová L. Monesin-containing pharmaceutical composition for treating diseases associated with deregulated Wnt pathway.

Grekov I, Pombinho A, Šíma M, Kobets T, Bartůněk P, Lipoldová M. Pharmaceutical composition containing diphenyleneiodonium for treating diseases caused by parasites of Trypanosomatidae species

Rejman D, Pohl R, Bartůněk P, Pombinho AR, Krásný L, Látal T. Lipophosphonoxins, method of their preparation and use

Rejman D, Pohl  R, Bartůněk P, Pombinho AR, Krásný L, Látal T. Lipophosphonoxins, method of their preparation and use

Novák P, Sedlák D, Bartůněk P, Kotora M. Ligands of estrogen receptors α and β, method of their preparation and pharmaceuticals comprising them

Novák P, Sedlák D, Bartůněk P, Kotora M. Ligands of estrogen receptors α and β, method of their preparation and pharmaceuticals comprising them

Novák P, Sedlák D, Bartůněk P, Kotora M. Estrogen receptors alpha and beta ligands, method for their preparation and pharmaceutical agents comprising thereof

Tjarks W, Bartunek P, Sedlak D, Carborane compounds and methods of use thereof.

Tjarks W, Bartunek P, Sedlak D, Carborane compounds and methods of use thereof.

Hocek M, Tokarenko A, Smolen S, Hajdúch M, Džubák P. Substituted heteropentadieno-pyrrolopyrimidine ribonucleosides for therapeutic use.

Hocek M., Tokarenko A, Smoleń S, Džubák P, Hajdúch M. Substituted heteropentadieno-pyrrolopyrimidine ribonucleosides for therapeutic use.

Hocek M, Tokarenko A, Smoleń S, Džubák P, Hajdúch M. Substituted heteropentadieno-pyrrolopyrimidine ribonucleosides for therapeutic use.

Hocek M, Tokarenko A, Smoleń S, Džubák P, Hajdúch M. Substituted heteropentadieno-pyrrolopyrimidine ribonucleosides for therapeutic use.

Kaplánek R, Bříza T, Havlík M, Rak J, Kejík Z, Džubák P, Hajdúch M, Konečný P, Štěpánková J, Králová J, Král V. Benzoisothiazole-1,1-dioxide-3-hydrazones and their use in anticancer therapy.

Hocek M, Nauš P, Caletková O, Džubák P, Hajdúch M. Substituted 7-dezapurin ribonucleosides.

Kaplánek R, Bříza T, Havlík M, Rak J, Kejík Z, Džubák P, Hajdúch M, Konečný P, Štěpánková J, Králová J, Král V. Dioxocyclobutenyl hydrazones and their anticancer activity.

Kaplánek R, Jakubek M, Havlík M, Rak J, Bříza T, Džubák P, Hajdúch M, Konečný P, Štěpánková J, Králová J, Král V. Caffeine-8-hydrazones as novel cytostatics for the treatment of oncologic diseases.

Rak J, Kaplánek R, Štulcová T, Drašar P, Havlík M, Bříza T, Džubák P, Hajdúch M, Konečný P,  Štěpánková J, Králová J, Král V. Cholyl hydrazones and their use in the treatment of tumor and leukemia diseases.

Havlík M, Kaplánek R, Dolenský B, Rak J, Bříza T, Džubák P, Hajdúch M, Konečný P, Štěpánková J, Králová J, Král V. Asymmetric Troger bases with hydrazone group and their use in the treatment of oncologic diseases.

Krejčí P, Hradil P, Hlaváč J, Hajdúch M. Derivates of 2-phenyl-3-hydroxyquinoline-4(1h)-one and methods of their preparation and utilization.

Šarek J, Spáčilová P, Hajdúch M. Triperpenoid 2-deoxy glycosides and use thereof as medicaments.

Šarek J, Hajdúch M, Svoboda M, Nováková K, Spáčilová P, Kubelka T, Biedermann D. Method of preparation of a soluble formulation of water-insoluble pentacyclic and tetracyclic terpenoids, a soluble formulation of a pentacyclic or tetracyclic terpenoid and a pharmaceutical composition containing this soluble formulation.

Šarek J, Svoboda M, Hajdúch M. Method of preparation and isolation of betulin diacetate from birch bark from paper mills and its optional processing to betulin.

Hajdúch M, Šarek J. Triterpenoid derivatives.

Fischer P, Šarek J, Blaney P, Collier P, Ferguson J, Hull JD, Hajdúch M. Solvates of 3.Beta, 28-diacetoxy-18-oxo-19, 20, 21, 29, 30-pentanorlupan-22-oic acid, processes for their preparation and pharmaceutical compositions thereof.

Rak J, Kaplánek R, Štulcová T, Drašar P, Havlík M, Bříza T, Džubák P, Hajdúch M, Konečný P, Stěpánková J, Králová J, Král V. Asymetric troger bases with hydrazone group and their use in the treatment of oncologic diseases

Paruch K, Petrůjová M. Furopyridines as inhibitors of protein kinases.

Paruch, K.; Carbain, B.; Havel, S.; Všiansky, V.; Nikulenkov, F.; Krejčí, L. Substituted propanamides as inhibitors of nucleases.

Paruch K, Petrůjová M. Substituted furo[3,2-b]pyridines intended for use as medicaments.

Paruch K, Petrůjová M, Němec V. Furopyridines as inhibitors of protein kinases.

Paruch K, Petrůjová M, Němec V. Furopyridines as inhibitors of protein kinases.

Damborsky J, Nikulenkov F, Sisáková A, Havel Š, Krejčí L, Carbain B, Brezovsky J, Daniel L, Paruch K. Pyrazolotriazines as inhibitors of nucleases.

Damborsky J, Nikulenkov F, Sisáková A, Havel Š, Krejčí L, Carbain B, Brezovsky J, Daniel L, Paruch K. Pyrazolotriazines as inhibitors of nucleases.

Damborsky J, Nikulenkov F, Sisáková A, Havel Š, Krejčí L, Carbain B, Brezovsky J, Daniel L, Paruch K. Pyrazolotriazines as inhibitors of nucleases.

Bryja, V; Janovská, P.; Gregorová, M.; Němec, V.; Khirsariya, P.; Paruch, K. 4-(1H-imidazol-5-yl)-1H-pyrrolo[2,3-b]pyridines for use in the treatment of leukaemias, lymphomas and solid tumors. AU 2019246220 B2